Financial Data and Key Metrics Changes - Zymeworks reported revenue of $1.9 million for Q1 2022, up from $0.6 million in Q1 2021, primarily from research support and partner payments [13] - Research and development expenses increased to $62.5 million in Q1 2022 from $44.3 million in Q1 2021, driven by higher clinical trial expenses for zanidatamab and restructuring costs [13][14] - General and administrative expenses rose to $12.1 million in Q1 2022 from $1.3 million in Q1 2021, including a non-cash stock-based compensation recovery of $5.1 million [15][16] - The net loss for Q1 2022 was $72.7 million, compared to $44.6 million in Q1 2021, attributed to increased operating expenses [17] - Cash resources were $300.5 million as of March 31, 2022, expected to fund operations into the second half of 2023 and beyond [19] Business Line Data and Key Metrics Changes - The increase in research and development expenses was primarily due to the initiation of the HERIZON-GEA-01 study and related drug manufacturing expenses [14] - The restructuring program led to severance and other expenses, impacting general and administrative costs [15][16] Market Data and Key Metrics Changes - The HERIZON-BTC-01 study completed enrollment ahead of schedule, with expectations to lock the study database by the end of 2022 and share results by early 2023 [22][24] - The FDA granted zanidatamab breakthrough therapy designation for patients with previously treated HER2-gene amplified biliary tract cancer, allowing for accelerated approval processes [24] Company Strategy and Development Direction - The company aims to build shareholder value by enabling patients to return home disease-free, focusing on developing therapies for hard-to-treat cancers [10] - Zymeworks is actively pursuing new partnerships and collaborations to extend its cash runway beyond 2023 [19][39] - The corporate goal includes advancing two new product candidates utilizing proprietary platform technologies and submitting two IND applications by the end of 2024 [37][40] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that increased operating expenses in Q1 2022 are expected to trend lower in upcoming quarters due to the completion of enrollment in clinical studies [18] - The company is focused on improving its balance sheet and has successfully closed a public offering despite challenging macroeconomic conditions [38] - Management emphasized the importance of integrating partnerships and collaborations throughout the product portfolio to enhance long-term value [51][76] Other Important Information - The company is in the process of selecting a new Chief Scientific Officer and has made significant progress in restructuring efforts [20][21] - Zymeworks is advancing its second clinical candidate, ZW49, and has completed enrollment in its expansion cohorts [32][33] Q&A Session Summary Question: Update on ASCO expectations and patient numbers - Management indicated that the patient numbers for ASCO presentations will be similar to previous Phase 2 data presentations, with interim data cuts expected [47] Question: Preference for early-stage platform deals versus specific asset transactions - Management is focused on integrating partnerships throughout the product portfolio to enhance development timing and broaden program scope [51] Question: Interpretation of ASCO's decision regarding CDK-46 combo presentation - Management noted that the decision was based on the maturity of the data, with plans to present a more mature version later [55] Question: Strategic updates on ZW49 and tumor types - Management is working on determining the next clinical study for ZW49 and will provide updates as soon as they have certainty [56] Question: Benchmarks for HERIZON-BTC in second-line disease - Management highlighted that there is significant unmet need in biliary tract cancer, and they expect better response rates than current chemotherapy options [63] Question: Proportion of patients enrolled in China and Korea for BTC - Management confirmed global enrollment for the study, with a focus on cooperation with BeiGene for regulatory discussions [80] Question: Data expectations from other zanidatamab indications - Management is enrolling in a Phase 2 study for front-line colorectal cancer but has not provided specific timelines for data presentation [90]

zymeworks Barclays Global Healthcare Conference Neil Klompas NYSE: ZYME Chief Operating Officer www.zymeworks.com 2 Legal Disclaimer This presentation includes "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of Canadian securities laws, or collectively, forward looking statements. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future ev ...

zymeworks Corporate Update and Year-End 2021 Financial Results Zymeworks Inc NYSE: ZYME February 24, 2022www.zymeworks.com 2 Legal Disclaimer This presentation Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of Canadian securities laws, or collectively, forward looking statements. Forward-looking statements include statements that may relate to implementation of our strategic priorities; clinical development of our product candidates, related clinical trials, an ...

Start Time: 16:30 January 1, 0000 5:19 PM ET Zymeworks Inc. (NASDAQ:ZYME) Q4 2021 Earnings Conference Call February 24, 2022, 16:30 PM ET Company Participants Kenneth Galbraith - Chair and CEO Chris Astle - SVP and CFO Neil Klompas - COO Neil Josephson - CMO Jack Spinks - Manager of IR Conference Call Participants Yigal Nochomovitz - Citigroup Akash Tewari - Jefferies Operator Thank you for standing by. This is the conference operator. Welcome to the Zymeworks Fourth Quarter and Year-End Results Conference ...

Company Overview - Zymeworks is developing multifunctional therapeutics through its proprietary platforms, leading the paradigm shift in drug development[4] - The company's lead asset, zanidatamab, is a bispecific antibody with the potential to become a new foundational HER2-targeted therapy[4] - Zymeworks' platforms enable the creation of tailor-made biotherapeutics with modular and scalable designs[12, 13] Partnership and Revenue - Zymeworks has received over $225 million in partnership revenue with more than $8.5 billion in total deal value[16] - Royalty percentages from partnerships range from low-mid single digits to tiered up to 20% for specific products and territories[16] Clinical Pipeline - Zanidatamab - Zanidatamab monotherapy in HER2-expressing late-line biliary tract cancer (BTC) showed a confirmed partial response (cPR) rate of 40% and a disease control rate (DCR) of 65%[33] - Zanidatamab plus chemotherapy in HER2+ first-line gastroesophageal adenocarcinoma (GEA) demonstrated a 93% confirmed objective response rate (cORR) for the proposed Phase 3 regimen[42] - Zanidatamab plus chemotherapy in HER2+ 3L+ breast cancer showed a confirmed objective response rate (cORR) of 36.4% and a disease control rate (DCR) of 86.4%[52] Clinical Pipeline - ZW49 - ZW49, a bispecific ADC for HER2-expressing cancers, has shown multiple confirmed responses and stable disease in several tumor types[27] - Phase 1 clinical data for ZW49 is expected to be reported at a medical meeting in 2022[30] Upcoming Milestones - Clinical data milestones for zanidatamab in 1L HER2+ GEA, 1L HER2+ breast cancer, and 3L+ HER2+ HR+ breast cancer are expected in the first half of 2022[54] - Phase 1 dose escalation and expansion cohorts for ZW49 are ongoing in 2022[54]

zymeworks Jefferies London Healthcare Conference Presentation November 18th – 19th Ali Tehrani - President & CEO www.zymeworks.com NYSE: ZYME Undergoing Transformation En Route Towards Commercialization 2023 2024 2025 2026 Biliary Tract BLA Second-Line üFast-to-Market Strategy üSingle-agent, single-arm üUS Accelerated Approval Gastroesophageal sBLA First-Line ü Expand Strategy ü Zani + Chemo ± PD1 Biliary Tract sBLA First-Line ü Expand Strategy ü Zani + Chemo (± PD11) 3 BLAs in Gastrointestinal Cancers in N ...

zymeworks Making Therapies that Make a Difference CORPORATE OVERVIEW NYSE: ZYME 2021 Bloom Burton & Co. Healthcare Investor Conference www.zymeworks.com 2 Legal Disclaimer This presentation includes "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of Canadian securities laws, or collectively, forward looking statements. Forward-looking statements include statements that may relate to our plans, o ...